Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ: BLUE )

8.700 -0.080 (-0.91%)
Streaming Delayed Price Updated: 1:52 PM EST, Dec 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm
From Schall Law
Via GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. (BLUE) Investors
From Law Offices of Howard G. Smith
Via Business Wire
BLUE INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Peeling Back The Layers: Exploring bluebird bio Through Analyst Insights
Via Benzinga
Peering Into bluebird bio's Recent Short Interest
Via Benzinga
Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst
Biotech stocks are famously volatile. One analyst feels this one could be volatile enough to produce an outsized gain. 
Via The Motley Fool
BLUE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Bluebird bio Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why
The company is working to launch its Vertex-partnered gene-editing drug for sickle cell disease and beta thalassemia. 
Via Investor's Business Daily
bluebird bio, Inc. (NASDAQ: BLUE) Financial Restatement: Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc.
NEW YORK, NY - (NewMediaWire) - March 28, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click... 
Via NewMediaWire
Is Bluebird Bio Stock a Buy Now?
Are you feeling brave? 
Via The Motley Fool
Forecasting The Future: 6 Analyst Projections For bluebird bio
Via Benzinga
bluebird bio, Inc. (NASDAQ: BLUE) Financial Restatement: Kaplan Fox &amp; Kilsheimer LLP Investigates bluebird bio, Inc.
NEW YORK, NY - (NewMediaWire) - March 28, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click... 
Via TheNewswire.com
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
BLUEBIRD ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Bluebird Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Bluebird bio, Inc. (NASDAQ: BLUE) Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc. for Potential Securities Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Bluebird bio, Inc. (NASDAQ: BLUE) Investor Alert: Kaplan Fox &amp; Kilsheimer LLP Investigates bluebird bio, Inc. for Potential Securities Violations
NEW YORK, NY - (NewMediaWire) - March 27, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click... 
Via TheNewswire.com
The Law Offices of Frank R. Cruz Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
BLUE LOSS ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
From The Rosen Law Firm, P.A.
Via Business Wire
Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc. (NASDAQ: BLUE)
NEW YORK, NY - (NewMediaWire) - March 26, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click... 
Via NewMediaWire
Kaplan Fox &amp; Kilsheimer LLP Investigates bluebird bio, Inc. (NASDAQ: BLUE)
NEW YORK, NY - (NewMediaWire) - March 26, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click... 
Via TheNewswire.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
From bluebird bio, Inc.
Via Business Wire
bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call
From bluebird bio, Inc.
Via Business Wire
Earnings Scheduled For March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. 
Via Benzinga
Why Bluebird Bio Stock Flew Higher Than the Market Today
The company was thrown a financial lifeline. 
Via The Motley Fool
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
From bluebird bio, Inc.
Via Business Wire
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place 
Via MarketBeat
Why Bluebird Bio Stock Dived Into the Red on Tuesday
The biotech has had a tough time of it over the past few years; a pundit's revised take on the company won't improve that situation. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.